Dexrazoxane vs no cardioprotective intervention or placebo
Overall survival (Illustrative comparative risks reported as number of alive participants) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall survival (Illustrative comparative risks reported as number… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
- Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes onlyHR 1.04 [0.88, 1.23]4 studies · 4 participantsModerate